Comparative Pharmacology
Head-to-head clinical analysis: FOVANE versus LORAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOVANE versus LORAZ.
FOVANE vs LORAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity by inhibiting reuptake of serotonin at the synaptic cleft.
Binds to gamma-aminobutyric acid (GABA) type A receptors at the benzodiazepine binding site, potentiating the effect of GABA, leading to increased chloride ion influx, neuronal hyperpolarization, and inhibition of neurotransmission.
Adults: 10 mg orally twice daily.
2-6 mg orally or intravenously daily in divided doses; usual range 2-10 mg/day
None Documented
None Documented
Terminal half-life: 12-15 hours; clinical context: supports twice-daily dosing, steady-state achieved by day 3.
Clinical Note
moderateClorazepic acid + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Fluticasone propionate."
Clinical Note
moderateLorazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Fluticasone propionate."
Clinical Note
moderateLorazepam + Haloperidol
"The risk or severity of adverse effects can be increased when Lorazepam is combined with Haloperidol."
Clinical Note
moderateTerminal elimination half-life: 12–15 hours in healthy adults. Extended in elderly (15–20 hours), hepatic impairment (up to 50 hours), and obesity.
Renal: 60% unchanged; fecal: 30% (as metabolites); biliary: 10%.
Renal: ~85% as glucuronide conjugates and ~10% as unchanged drug. Biliary/fecal: ~5%.
Category C
Category C
Benzodiazepine
Benzodiazepine
Lorazepam + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Lorazepam."